Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug;39(4):131-134.
doi: 10.18773/austprescr.2016.053. Epub 2016 Aug 1.

Rituximab in autoimmune diseases

Katrina L Randall  1
Affiliations
Review

Rituximab in autoimmune diseases

Katrina L Randall. Aust Prescr. 2016 Aug.

Abstract

Rituximab is a monoclonal antibody that depletes B cells from the circulation. It was originally used to treat lymphoma but is increasingly used for the treatment of autoimmune diseases. Rituximab was found to be effective in randomised controlled trials for rheumatoid arthritis, granulomatosis with polyangiitis and other antineutrophil cytoplasmic antibody-associated vasculitides. However, evidence of efficacy is very limited for many other autoimmune conditions. Before starting rituximab, it is important to check the patient's baseline immunoglobulins and immunisation status. Patients should also be screened for latent infections and other contraindications.

Keywords: B lymphocyte; antineoplastic agent; antineutrophil cytoplasmic antibody; autoantibody; lymphoma; rituximab.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, et al. Rituximab Consensus Expert Committee . Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909-20. 10.1136/ard.2010.144998 - DOI - PMC - PubMed
    1. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-68. 10.1038/sj.onc.1206939 - DOI - PubMed
    1. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. REFLEX Trial Group . Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. 10.1002/art.22025 - DOI - PubMed
    1. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. DANCER Study Group . The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400. 10.1002/art.21778 - DOI - PubMed
    1. Peterfy C, Emery P, Tak PP, Ostergaard M, DiCarlo J, Otsa K, et al. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis 2016;75:170-7.. 10.1136/annrheumdis-2014-206015 - DOI - PMC - PubMed